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*p< 0.05, ***p<0.001 versus vehicle control (0 mg/kg) (Tukey's posthoc test)




































































































































***p<0.001 versus vehicle control (0 mg/kg) (Tukey's posthoc test)

































*p<0.05, **p<0.01, and ***p<0.001 versus vehicle control (0 mg/kg) (Tukey's posthoc test)
#p<0.05, ##p<0.001 and ###p<0.001 versus 80mg/kg PTZ group (0 mg/kg) (Tukey's posthoc test)
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Figures	6	and	7	represent	the	dose	response	of	AZ66	on	the	number	of	chemically	induced	
seizures.		In	figure	6,	all	groups	were	significantly	different	at	a	p-value	of	.001	when	compared	
to	the	vehicle.		When	compared	to	the	lone	dose	of	80	mg/kg	subcutaneous	dose	of	PTZ,	only	
the	highest	dose	of	AZ66	(30	mg/kg)	proved	to	be	significant	(p<.001).	Figure	7	demonstrates	
the	effects	of	increasing	the	dose	of	AZ66	on	the	number	of	major	seizures.		All	doses	of	AZ66	
differed	from	the	vehicle	at	a	p-value	<	.05.		When	the	number	of	major	seizures	produced	
when	pretreated	with	AZ66	was	compared	to	the	lone	dose	of	the	s.c.	80	mg/kg	dose	of	PTZ,	
the	20	mg/kg	and	the	30	mg/kg	proved	to	be	significantly	different	(p<.05).		Both	of	these	
graphs	illustrate	that	as	the	dose	of	AZ66	increased	so	did	the	frequency	of	the	seizures	
increased.			
	
IV. Discussion	
The	subcutaneous	80mg/kg	dose	of	PTZ	was	chosen	due	to	the	quick	response	time,	
frequency	of	the	seizures,	and	the	clear	distinctions	between	mini	and	major	seizures.		
However,	the	effects	of	AZ66	were	the	opposite	of	what	we	expected.		When	screening	AZ66,	
the	compound	actually	decreased	the	seizure	latency	time	while	increased	the	number	of	
seizures	as	the	dose	increased.		These	seizures	were	more	violent	and	resulted	in	death	at	the	
30	mg/kg	dose	of	AZ66.			
While	AZ66	may	attenuate	seizures	induced	by	cocaine,	it	does	not	do	so	for	PTZ	induced	
seizures.		PTZ	exerts	its	effects	by	acting	as	a	GABAa	receptor	antagonist.		GABA	is	one	the	most	
important	inhibitory	neurotransmitters	in	the	central	nervous	system	(Heard,	Palmer,	&	
Zahniser	2008)	and	is	the	target	of	many	AEDs.		Because	AZ66	did	not	perform	as	expected,	it	is	
reasonable	to	assume	that	AZ66	does	not	directly	act	on	the	GABA	pathway.		This	is	consistent	
with	the	fact	that	cocaine	indirectly	induces	its	effects	on	GABA	receptors	through	
neurotransmitters	(Centonze,	et	al.,	2002).		It	is	likely	that	sigma	antagonists	are	not	be	
effective	in	treating	GABA-mediated,	chemically	induced	seizures.		This	assumption	is	
supported	by	the	fact	that	AZ66	is	effective	at	reducing	seizures	induced	by	cocaine,	but	not	
seizures	induced	by	PTZ.		However,	because	cocaine	induced	seizures	are	drug	refractory,	AZ66	
could	still	prove	useful	in	other	types	of	epilepsy.		
	
V. Future	Studies	
	 Futures	studies	for	this	project	are	needed.		First	off,	AZ66	needs	to	be	tested	for	
efficacy	in	reducing	electrically	induced	seizures	using	the	Maximal	Electroshock	seizure	test.		It	
is	necessary	to	perform	this	test	to	rule	out	the	possibility	of	AZ66’s	antiepileptic	effects	in	a	
different	seizure	type.		While	AZ66	is	not	effective	in	attenuating	seizures	caused	by	chemical	
stimulation,	it	may	be	beneficiary	in	electrically	kindled	seizures.		From	there,	PTZ	and	MES	
induced	convulsion	tests	should	be	run	on	selective	antagonists	for	both	sigma	1	and	sigma	2	
receptors	to	find	which	is	responsible	for	the	increase	of	the	convulsions	seen	when	using	the	
non-selective	sigma	antagonist	AZ66.	
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